What's Happening?
The Advanced Research Projects Agency for Health (ARPA-H) has launched the Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program, committing up to $33.7 million in its first year. This four-year program, with a total budget of $62.7
million, aims to create the world's first reliable, FDA-authorized clinical agentic AI system for 24/7 cardiovascular care. The goal is to establish a digital member of the clinical care team that can autonomously support heart failure patients between visits and escalate to human care teams when necessary. Selected teams, including Atman Health, Tempus AI, and Updoc, will develop patient-facing clinical AI agents. Stanford University will develop a supervisory AI agent to monitor these clinical agents for safety and out-of-distribution behavior. Duke University and Kaiser Permanente will focus on scalable implementation strategies within health systems, particularly in rural and underserved communities. The program will engage the U.S. Food and Drug Administration (FDA) throughout its lifecycle to develop the necessary regulatory framework for this new class of patient-facing clinical AI.
Why It's Important?
Cardiovascular disease is the leading cause of death in the U.S., with over 200,000 preventable deaths annually, and nearly half of U.S. counties lack a single cardiologist. The current care model, reliant on scarce in-person specialist visits, leads to avoidable hospitalizations, delayed medication adjustments, poor adherence, and clinician burnout, especially in underserved areas. The ADVOCATE program seeks to transform this by providing continuous, geography-independent cardiovascular specialty care. If successful, this initiative could save lives, reduce preventable hospitalizations, and generate an estimated $28 billion in annual cost savings for the heart failure population alone. By developing an FDA-authorized autonomous AI clinician-extender, the program aims to improve access to care, enhance patient outcomes, and alleviate the burden on the healthcare workforce, particularly in regions with limited medical resources.
What's Next?
The selected teams are tasked with developing their respective AI systems, with the patient-facing clinical AI agent teams (TA1) required to submit a first-of-its-kind FDA-authorization package within 24 months of the contract award. Throughout the program, ARPA-H will collaborate closely with the FDA to establish a regulatory framework for this new class of clinical AI. Performers will also work to define shared evaluation standards, interoperability requirements, and reimbursement pathways to ensure the system's scalability and integration into existing healthcare infrastructure. The Johns Hopkins University Applied Physics Laboratory (JHU/APL) will serve as an external evaluation partner, providing independent assessment of technical performance and clinical outcomes to validate results and strengthen regulatory confidence. The ultimate goal is to deploy these AI agents in diverse care settings, with a focus on rural and underserved communities, to demonstrate their real-world impact.
Beyond the Headlines
The ADVOCATE program represents a significant step towards integrating autonomous agentic AI into direct patient care, pushing the boundaries of digital health. This initiative raises crucial questions about the evolving role of AI in medicine, particularly concerning patient trust, clinical accountability, and the ethical implications of AI making autonomous care decisions. The program's emphasis on developing a robust regulatory framework with the FDA is critical, as it will set precedents for future AI-driven medical technologies. Furthermore, the focus on addressing healthcare disparities in rural and underserved communities highlights the potential of AI to democratize access to specialized medical care. The success of ADVOCATE could pave the way for agentic AI to become a new, autonomous member of clinical teams across various medical conditions, fundamentally reshaping how healthcare is delivered and managed in the United States.
